Liraglutide therapy beyond glycemic control: An observational study in Indian patients with type 2 diabetes in real world setting

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 317-322

  Kesavadev, Jothydev ^a   Shankar, Arun ^a   Krishnan, Gopika ^a   Jothydev, Sunitha ^a  

^a Jothydev's Diabetes and Research Center   (India)

Author keywords

Blood pressure; GLP 1 analog; India; Lipid profile; Liraglutide; Obesity; Type 2 diabetes; Weight loss

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INDIAN; KIDNEY FUNCTION TEST; LIPID ANALYSIS; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SATIETY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT REDUCTION;

EID: 84867687757     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S27886     Document Type: Article

References (18)

1. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96(6):1654-1663.
2. Misra A, Sharma R, Gulati S, et al; National Dietary Guidelines Consensus Group. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. Diabetes Technol Ther. 2011;13(6):683-694.
3. Anjana RM, Pradeepa R, Deepa M, et al; on behalf of the ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54(12): 3022-3027.
4. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573-584.
5. Victoza® (liraglutide [rDNA origin] injection). Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2011/022341s004 lbl.pdf. Accessed September 1, 2011.
6. Kesavadev J, Shankar A, Shamsudeen J, et al. Telefollow up and SMBG via "DTMS"-A cost effective tool for A1c lowering [abstract] Diabetes. 2010;59(Suppl 1):A546.
7. Rosner B. Fundamentals of Biostatistics. 5th ed. Pacific Grove, CA: Duxbury; 2000:80-240.
8. Riffenburgh RH. Statistics in Medicine. 2nd ed. San Diego, CA: Academic Press; 2005:85-125.
9. Sunder Rao PSS, Richard J. An Introduction to Biostatistics: A manual for students in health sciences. New Delhi, India: Prentice Hall of India; 1996:86-160.
10. Eng J. Sample size estimation: How many individuals should be studied? Radiology. 2003;227:309-313.
11. Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Rev Endocrinol Metabol. 2009;4(2):119-129.
12. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3): 268-278.
13. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1): 84-90.
14. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
15. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetpTZD). Diabetes Care. 2009;32(7):1224-1230.
16. Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) metiSU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 mettSU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-2055.
17. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
18. Jendle J, Nauck MA, Matthews DR, et al; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163-1172.